Most cells acquire iron from plasma transferrin and it is the transferrin receptor that is responsible for the internalization of transferrin-bound iron and its subsequent intracellular release. Plasma concentrations of the receptor re ect cellular receptor numbers and may be determined by enzyme immunoassay on automated analysers. Although determination of receptor concentrations may provide little additional value to existing measures of iron status, particular circumstances may dictate the use of these assays. This review summarizes transferrin receptor physiology and biochemistry, the limitations of the methodology that is currently available and the clinical application of assays (a) in monitoring changes in the rate of erythropoiesis, (b) as an indicator of developing iron de ciency and (c) in identifying iron de ciency in patients with anaemia of chronic disease.
Introduction Iron metabolism
Most of the iron in the body is in the erythrocytes as haemoglobin; iron is also found (in trace concentrations) in many of the proteins involved in the utilization of oxygen. The major pathway of iron turnover 1 is the synthesis and breakdown of haemoglobin via the plasma, with only limited exchange with the environment through absorption and excretion (see Fig. 1 ).
The transferrin receptor
Almost all cells in the body obtain iron from the plasma protein transferrin. However, transferrin has a very high a¤nity for iron at neutral pH and iron release requires a speci¢c membrane receptor. This is the transferrin receptor, 2 which is coded for by a gene (TFRC) on chromosome 3, and consists of two identical protein subunits each of molecular mass 95 kDa (see Fig. 2 ). Transferrin binds to the receptor, the complex is then internalized and iron is released when the pH of the internal vesicles is reduced to about 5¢5. The way in which iron ¢nally crosses the vesicular membrane into the cell cytoplasm remains largely unknown. After iron release, apotransferrin returns to the circulation and can undertake further cycles of iron uptake and delivery.
The cells that require the most iron are the nucleated red cells in the bone marrow which synthesize haemoglobin; these cells have the greatest number of transferrin receptors. 4 The number of transferrin receptors on other cells re£ects iron requirements, but these are generally much lower. Transferrin receptor synthesis is also controlled by iron supply. 5 Reduction of iron supply in cultured cells, by the addition of a chelating agent to the medium, leads to increased synthesis. The addition of iron reduces the level of synthesis. This regulation involves iron regulatory elements at the 3'-untranslated region of the receptor mRNA. In the absence of iron the iron regulatory protein (IRP) binds to the RNA, thereby stabiliz ing it and permitting synthesis of the peptide. In the presence of adequate iron concentrations, binding of iron by the IRP changes the conformation of the protein and prevents its binding to the mRNA. The mRNA is rapidly broken down and synthesis of transferrin receptors is reduced. A gene showing 66% homology to TFRC was recently isolated 6 and mapped to chromosome 7 (7q22). The expressed protein (TFR2) binds transferrin, but its role in iron metabolism is little understood.
Serum transferrin receptor (sTfR)
In 1986, Kohgo et al. 7 reported that transferrin receptors were detectable in plasma by immunoassay. Since then there has been much investigation of the physiological and diagnostic signi¢cance of circulating sTfR. 8 The protein is derived by Review Article Figure 1 . The major pathways of iron metabolism in man. The numbers in the boxes are amounts in mg; the numbers against the arrows are mg Fe per day. The iron in muscle is largely haem iron; in hepatocytes the 200 mg Fe is largely ferritin iron. proteolysis at the cell membrane and circulates bound to transferrin. Plasma concentrations re£ect the number of cellular receptors and, in patients with adequate iron stores, the number of nucleated red cells in the bone marrow. As the number of cellular transferrin receptors per cell increases in iron de¢ciency, concentrations rise when erythropoiesis becomes iron-limited.
Measurements of circulating sTfR have been used as an indicator of the rate of erythropoiesis 2 and as an indicator of iron de¢ciency. 9 sTfR concentrations are similar in normal men and women, unlike serum ferritin (sFn) concentrations, which are lower in women before the menopause. When normal subjects are subjected to quantitative phlebotomy, sFn concentrations fall steadily as iron stores are depleted but there is little change in sTfR concentration. As iron stores become exhausted (sFn 515 mg/ L), sTfR concentrations rise and continue rising as haemoglobin concentrations fall. 9 In this study, the increased rate of erythropoiesis during phlebotomy had little e¡ect on sTfR concentrations as long as iron stores were adequate, so that most of the increase in sTfR concentration must be due to iron de¢ciency rather than increased erythropoiesis. However, the rate of phebotomy was only 250 mL/week (up to 1000 mL/ week may be removed during treatment of haemochromatosis) and higher rates may cause an immediate increase in sTfR concentrations during phlebotomy. The ratio sTfR/sFn gives a linear relationship with body iron content (see Fig. 3 ) which is of value in assessing iron stores in epidemiological studies. This relationship with storage iron content has attracted considerable interest as it has been demonstrated that sTfR concentrations are elevated in patients with chronic disease lacking stainable iron in the bone marrow, but remain within the reference range in those with adequate amounts of storage iron (see later). Table 1 summarizes conditions that are associated with changes in sTfR concentration. Increased concentrations are indicative of an increased rate of erythropoiesis or iron de¢ciency; these topics are discussed later. sTfR concentrations with di¡erent assay systems cannot be directly compared as reference ranges di¡er (see later).
Assays for the sTfR
Three enzyme immunoassay kits for the determination of sTfR concentration have been evaluated for the Medical Devices Agency 10 (see Table 2 ). All three kits have been used in the investigation of iron de¢ciency (Ramco, 11 R&D 12,13 and Orion 14, 15 ) and have been approved for diagnostic purposes in the USA by the FDA. The manufacturers do not provide detailed information about the transferrin receptor preparations employed as antigen and standard but some insight may be obtained from the original descriptions of assays. Kohgo et al. 7 puri¢ed the transferrin receptor protein from normal human placenta after saturation with transferrin, solubilization in detergent, gel ¢ltration, a¤nity chromatography and dissociation from transferrin at pH 5¢ 0. The receptor migrated at a molecular mass of 95 kDa on sodium dodecyl sulphate polyacrylamide gel electrophoresis. Two commercially available monoclonal antibodies against the transferrin receptor, OKT9 and B3/2S, were used in a two-site immunoradiome tric assay. 7 Flowers et al. 16 also puri¢ed the receptor from human placenta, but used the transferrin^transferrin receptor complex for immunization of mice to raise monoclonal antibodies and as a calibrant.
The di¡erent reference ranges of the three commercial assays described in Table 2 re£ect the di¡erences in preparations of transferrin receptor used to raise antibodies and as a standard in the various assays.
Performance
Ðkesson et al. 17 10 found similar imprecision and noted some assay drift for the Orion (IdeA), Ramco and R&D assays. Replicates of several control serum samples were tested immediately after the standards on an immunoassay plate and at the end of the run. For the Ramco assay, mean values (+standard deviation, SD) at the end of the run of samples were 94% (+11%) of those at the beginning, for Orion 88% (+11%) and for R&D 74% (+6%). Regression analysis of 20 replicates of a control serum (ten at the beginning of the sample run and ten at the end) con¢rmed that there was signi¢cant assay drift for the R&D assay. Between-batch variations for control samples at di¡ering concentrations were 1¢5^15¢ 0% (Ramco), 3¢5^10¢3% (R&D) and 6¢3^10¢5% (Orion). The determined sensitivity was adequate for clinical purposes for the three assay systems. Ðkesson et al., 17 Kuiperkramer et al. 18 and Worwood et al. 10 all comment on the di¡erences in both units and absolute amounts for sTfR concentrations. For the four kits evaluated there are four di¡erent units (nmol/L, mg/ mL, mg/L, kU/L) and four di¡erent reference ranges. At the present time, sTfR is not included in the national external quality control schemes for the UK (UK NEQAS) and Wales (WEQAS).
The information provided by the manufacturers shows good recovery of calibrant linearity, but some problems with interference. Although serum is the preferred matrix, the R&D and Ramco assays give the same results with EDTA-, heparin-and citrateplasma. Orion states that EDTA-plasma is not acceptable. It is recommended that serum samples are stored for no longer than 2 days at room temperature, 7 days at 2^88C, 1^6 months at 7208C and 1 year at 7708C. Repeated freezing and thawing is not recommended. Moderate haemolysis is not a problem, with no interference below haemoglobin concentrations of 1¢25 g/L (R&D), 2¢ 0 g/L (Orion) and 15 g/L (Ramco). There is no interference from serum bilirubin at concentrations of 51700 mmol/L (R&D) or 280 mmol/ L (Orion). However, Ramco noted that addition of bilirubin at a concentration of only 17 mmol/L (10 mg/ mL) caused a 16% increase in apparent sTfR concentration. There was also an increase in sTfR concentration after increasing the sTf concentration to about twice the upper limit of normal.
Transferrin receptors in diagnosis
For a review of this topic see Cook. 19 
Reference ranges
The di¡erent units in use make it di¤cult to compare the various reported investigations, but Choi et al. 20 have provided information on changes in development from birth to adulthood using the Orion IDeA assay. sTfR concentrations are high in neonates and decline until adult concentrations are reached at 17 years. In pregnancy, sTfR concentrations increase with gestational age and return to non-pregnancy values 12 weeks after delivery. 21 Ann Clin Biochem 2002; 39: 221-230 
Erythropoiesis
The function of the transferrin receptor in delivering iron to the immature red cell immediately suggested an application in the clinical laboratory for the assay of circulating sTfR. The use of the assay to monitor changes in the rate of erythropoiesis has been explored by several authors. 22^24 When iron supply is not limiting erythropoiesis, the assay can provide a replacement for the now largely forgotten ferrokinetic investigations, which required the injection of radioactive iron. 25
Iron de ciency
The major proposed application of the sTfR assay in the clinical laboratory has been to detect patients with an absence of stored iron (ferritin and haemosiderin in cells). This is because of the up-regulation of transferrin receptor synthesis in iron de¢ciency. Skikne et al. 26 and Punnonen and Rajamaki 27 have shown that, in healthy subjects, sTfR levels provide excellent discrimination between those lacking storage iron and those with adequate amounts of storage iron. This has been con¢rmed by iron supplementation of irondepleted, non-anaemic women. 28 Olivares et al. 29 showed that, in infants (8^15 months), the sTfR concentration was very sensitive to iron de¢ciency and increased with increasing de¢ciency from reduced iron stores to absent stores and anaemia. Detection of a lack of storage iron in patients with the anaemia of chronic disease is di¤cult because serum iron concentrations are low regardless of iron stores, and sFn concentrations, although re£ecting the level of iron stores, are higher than in healthy subjects. 30 In both iron-de¢ciency anaemia and the anaemia of chronic disease sTfR concentrations are also in£uenced by changes in the rate of erythropoiesis. Ine¡ective erythropoiesis (an increase in the number of immature red cells destroyed within the bone marrow) increases in iron-de¢ciency anaemia. 31 In the anaemia of chronic disease, erythropoiesis is normal or depressed. 31 Punnonen et al. 32 have demonstrated in patients with anaemia of chronic disease that measurement of sTfR can distinguish between those lacking iron stores and those with adequate amounts of storage iron (see Fig. 4 ).
sTfR concentrations have been measured in a variety of conditions in which there is anaemia secondary to disease, but there is some disagreement about the clinical value of the assay for detecting an absence of storage iron. For example, in patients with rheumatoid arthritis, Nielsen et al. 33 and Zoli et al. 34 found no signi¢cant di¡erence in levels between patients without bone marrow storage iron and those with iron, and Kurer et al. 35 found that the measurement of sTfR did not improve the sensitivity and speci¢city for diagnosis of iron de¢ciency compared with the assay of sFn. In contrast, Suominen et al. 36 found that single values of sTfR predicted both true iron de¢ciency (absence of storage iron) and functional iron de¢ciency (iron-de¢cient erythropoiesis with adequate iron stores). In both cases, iron de¢ciency was de¢ned as a response to oral iron therapy. This is the most valuable information required by the clinician: i.e. will a patient respond to iron therapy, either oral or parenteral? It is possible that the level of in£ammation is important, as Zoli et al. 34 found a correlation between sTfR concentration and both erythrocyte sedimentation rate (ESR) and interleukin 1b concentrations in patients with active rheumatoid disease.
The anaemia of chronic renal failure is often due to an inability to synthesize adequate amounts of erythropoietin in the kidney. The anaemia responds rapidly to erythropoietin therapy unless the iron supply to the bone marrow is inadequate. As well as patients with no storage iron, those with normal amounts of stainable iron in the bone marrow and sFn concentrations 4100 mg/L may not respond to erythropoietin because they cannot supply iron to the marrow rapidly enough to satisfy the demand from the dividing red cells. There is little indication, so far, that sTfR concentrations are of value in predicting the response to erythropoietin and iron. 37 Ferna¨ndez-Rodrigues et al. 38 evaluated sTfR concentrations in clinically stable adults who had not received erythropoietin in the 3 months before the study but concluded that sTfR concentration was less reliable than sFn concentration for identifying patients without stainable iron in the bone marrow.
Although sTfR concentrations are less in£uenced by active disease than sFn concentrations, there are circumstances in which there is interference. Beesley et al. 39 and Williams et al. 40 found that sTfR concentrations were reduced in patients with clinical malaria and suggested that levels need to be interpreted cautiously as an indicator of iron status in this circumstance.
When sTfR concentrations are measured in unselected patients undergoing bone marrow aspiration, the diagnostic value for an absence of storage iron declines. Means et al. 41 found a signi¢cant di¡erence between mean sTfR concentrations in patients without stainable iron in the bone marrow and those with stainable iron. Nevertheless, 29% of patients with no stainable iron had normal concentrations of sTfR and 26% of patients with stainable iron had raised concentrations. The use of the sFn/sTfR ratio improved the speci¢city but not the sensitivity. Worwood et al. 10 
(c) The TfR-Fn index (sTfR/log sFn) for the same groups of patients. IDAˆ48 patients with iron-de ciency anaemia; COMBIˆ17 patients with anaemia of chronic disease and depleted bone marrow iron stores; ACDˆ64 patients with chronic disease and storage iron in the bone marrow. From reference 32 with permission.
Most comparisons of the diagnostic sensitivity and speci¢city of sTfR for diagnosis of iron de¢ciency have used stainable iron in the bone marrow or sFn as an indicator of iron de¢ciency. However, sTfR concentrations re£ect the number of receptors on nucleated red cells and concentrations probably rise in`functional' iron de¢ciency as well as in`absolute' iron de¢ciency (i.e. an absence of storage iron and an absolute reduction in body iron content). In functional iron de¢ciency there may be stainable iron in the bone marrow and a normal sFn concentration. 42 This may explain the discrepant results discussed above.
Although it has been claimed that sTfR measurements provide a sensitive indicator of iron de¢ciency in pregnancy, 43 questions remain about the decreased erythropoiesis in early pregnancy as this may mask iron de¢ciency at this time. 11 Choi et al. 20 found that increases in sTfR appeared to relate to increased erythropoiesis rather than iron depletion. Vandenbroek et al. 44 found that measurement of sTfR did not enhance the sensitivity and speci¢city for the detection of iron-de¢ciency anaemia in pregnant women from Malawi where anaemia and chronic disease are very prevalent.
Iron overload
Huebers et al. 23 and Baynes et al. 45 reported normal concentrations of sTfR in patients with genetic haemochromatosis (although some had been venesected) and also in African iron overload. 45 In contrast, Khumalo et al. 46 and Looker et al. 47 found lower mean values of sTfR in subjects with a raised transferrin saturation. However, there was considerable overlap with the reference range of sTfR concentration, and measurement of sTfR in iron overload is unlikely to be of diagnostic value.
Conclusion
When erythropoiesis is not limited by the iron supply to the bone marrow, sTfR concentrations correlate with the rate of erythropoiesis, whether e¡ective (producing erythrocytes) or ine¡ective (destruction of nucleated red cells in the bone marrow). However, when the iron supply to the bone marrow is inadequate for haemoglobin synthesis, sTfR concentrations increase as a result of stimulation of transferrin receptor synthesis on erythroblasts by iron de¢ciency. In iron-de¢ciency anaemia, there is loss of iron from the body, with levels of storage iron and then haemoglobin iron being depleted. The increase in sTfR concentration re£ects both an increase in ine¡ective erythropoiesis and an increase in the number of receptors as a result of up-regulation by lack of iron. In the anaemia of chronic disease, erythropoiesis is not usually increased and sTfR concentrations only increase if iron supply to the bone marrow is limiting. This usually occurs when iron stores are exhausted, but it can occur even in the presence of adequate amounts of storage iron (functional iron de¢ciency). This limitation is most obvious when patients are treated with erythropoietin and the rapid increase in the demand for iron for haemoglobin synthesis cannot be met even though sFn concentrations are normal and there is stainable iron in the bone marrow.
In most circumstances iron metabolism can be assessed by careful consideration of erythropoiesis (red cell count, haemoglobin, mean corpuscular haemoglobin, reticulocyte count) and storage iron (sFn), together with a measure of disease activity (liver function tests, ESR and C-reactive protein). The sTfR concentration may provide an earlier indicator of iron-de¢cient erythropoiesis than the erythrocyte indices, but this has not yet been clearly demonstrated. In the UK it is rare for a bone marrow aspiration to be carried out solely to determine the amount of storage iron, and the use of a single determination of sTfR concentration to replace bone marrow aspiration for this purpose has not been validated.
sTfR concentrations provide a valuable indicator of developing iron-de¢ciency erythropoiesis in healthy subjects and can be used to follow changes in the rate of erythropoiesis in patients with adequate amounts of storage iron. However, in general hospital practice, measurement of sTfR concentrations in individuals adds little to the existing repertoire of measures of iron status and needs to be evaluated with information about haemopoiesis.
From the analytical point of view, a major problem is the di¡erent units and reference ranges for these assays. This is intrinsic to the use of di¡erent calibrants and antibodies, but until there is agreement on common units and calibrants clinical use of the assays will be limited. This plea for standardization has been made in evaluations of the three kits 10,17 discussed above. Allen et al. 12 have recommended that natural plasma transferrin receptor should be used as the calibrator. sTfR assays are now becoming available on the current generation of automated analysers. The determination of sTfR concentrations will become less labour-intensive and expensive and should add to the diagnostic armoury for the investigation of erythropoieses in patients as well as of iron de¢ciency in population surveys. As with all the available assays of iron status, interpretation of sTfR concentrations requires an understanding of the physiology and biochemistry of the protein.
